If asymptomatic arrhythmias or non-documented symptomatic episodes occurred between routine follow-up visits, recurrence after ablation might have been missed in these patients, as previous studies have demonstrated.
At 2nd follow-up visit, one recurrence was registered.
Before their visit, for recurrence, 6 patients out of 20 were accurate within ± 5% of their Adjuvant! estimate.
At 1st follow-up visits, two recurrences were registered in the NMSC database.
Sensitivity Analysis At a threshold of ± 10%, 13 matched Adjuvant! after the oncology visit for both recurrence and mortality estimates.
At these visits, information on recurrence, cosmetic result and complications are registered (Appendix 2).
Follow-up was dated to the last documented clinic visit with all recurrences being confirmed by clinical investigation and, where appropriate, pathology.
During their regular postoperative follow-up visits, no tumor recurrence occurred in patient who received radical resections; however, 5 out of 8 patients who received liver-preserving surgery 62.5%%) had tumor recurrence (p = 0.005).
Thus, for each patient included in the cohort, the following information was extracted from NSCR/OPIS: patient demographics, previous and subsequent primary cancers, diagnosis and staging, cancer center referrals, treatment-related and cancer recurrence visits, and radiotherapy treatments.
The index visit was an active recurrence of uveitis for the other 7 patients.
